What must be done with antineoplastic HDs to prevent contamination?

Storing antineoplastic hazardous drugs (HDs) separately from non-hazardous drugs is essential to prevent contamination and maintain a safe environment. This practice aligns with the guidelines set forth by USP 800, which emphasizes the importance of minimizing the risk of exposure to hazardous materials.

When antineoplastic HDs are stored with non-HDs, there is a heightened risk that contaminants could spread, potentially exposing pharmacy staff, healthcare workers, and patients to harmful substances. The separate storage helps to ensure that any spills or leaks from HDs do not come into contact with non-HD medications, thereby reducing the likelihood of inadvertent exposure or contamination.

The requirement for clear labeling, while important, does not suffice on its own to prevent contamination. Clear labeling can aid in identifying HDs but does not address the physical separation necessary to ensure workplace safety. Storing in a common area might also lead to increased exposure risks, as it allows for more interaction with non-HD substances and increases the chance of cross-contamination. Thus, the key to preventing contamination lies in the proper storage of antineoplastic HDs apart from non-HDs.